Search
Ecabet
go.drugbank.com/drugs/DB05265InvestigationalEcabet is currently marketed in Japan as an oral agent for treatment of gastric ulcers and gastritis.
Glucosamine
go.drugbank.com/drugs/DB01296ApprovedGlucosamine is commonly used over the counter as a treatment for arthritic joint pain, although its acceptance as a medical therapy varies due to contradictory and findings with unclear clinical significance … [A231894,A232289] It is currently not approved as a prescription product by the FDA, but is widely available over the counter.
Silver nitrate
go.drugbank.com/drugs/DB11080ApprovedIt is often used as a precursor to other silver-containing compounds. … It is used in making photographic films, and in laboratory setting as a staining agent in protein visualization in PAGE gels and in scanning electron microscopy.
Arsanilic acid
go.drugbank.com/drugs/DB03006ExperimentalVet approvedAn arsenical which has been used as a feed additive for enteric conditions in pigs and poultry. It causes blindness and is ototoxic and nephrotoxic in animals. [PubChem]
Ciclesonide
go.drugbank.com/drugs/DB01410ApprovedInvestigationalCiclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.
Indopan
go.drugbank.com/drugs/DB01446ExperimentalIllicitIt was developed in the 1960's by Upjohn with the intention for use as an antidepressant. In the 1990's, indopan became regulated as a Schedule I controlled substance in the United states.
Normethadone
go.drugbank.com/drugs/DB11609ApprovedIllicitNormethadone is used as an opioid antitussive in combination with [DB11610]. It is marketed in Canada by Valeant under the tradename Cophylac.
Echothiophate
go.drugbank.com/drugs/DB01057ApprovedInvestigationalA potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia.
Tafamidis
go.drugbank.com/drugs/DB11644ApprovedInvestigational[A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]
Etelcalcetide
go.drugbank.com/drugs/DB12865ApprovedInvestigationalEtelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.